Literature DB >> 16939955

The role of oral mucositis on the systemic inflammation parameter IL-8 in febrile neutropenic cancer patients.

M A Stokman1, C S M Oude Nijhuis, F K L Spijkervet, E S J M de Bont, P U Dijkstra, S M G J Daenen, J A Gietema, W T A van der Graaf, H J M Groen, E Vellenga, W A Kamps.   

Abstract

PURPOSE: Cancer patients treated with cytostatic drugs often develop oral mucositis, considered to be a mucosal injury in which various cytokines, such as interleukin 8 (IL-8), may play a role. Plasma IL-8 is a systemic inflammatory response parameter. This study investigated whether oral mucositis affects plasma IL-8 levels in febrile neutropenic cancer patients. PATIENTS AND METHODS: Patients (n = 57) who were hospitalized with chemotherapy-induced neutropenic fever were scored for oral mucositis on the second day of hospitalization according to a validated oral mucositis assessment scale (OMAS) and WHO toxicity grading. Patients (n = 20) with a clinical sepsis or local bacterial infection were excluded from this evaluation. The remaining 37 patients were divided in groups with and without oral mucositis.
RESULTS: The difference in plasma IL-8 level between patients with and without mucositis was not significant (P = 0.7). Similarly no difference was observed in the degree and duration of granulocytopenia.
CONCLUSION: These results indicate that low-grade oral mucositis is not related to the systemic plasma IL-8 level in febrile neutropenic cancer patients without a clinical sepsis or local bacterial infection.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16939955     DOI: 10.1080/07357900600814698

Source DB:  PubMed          Journal:  Cancer Invest        ISSN: 0735-7907            Impact factor:   2.176


  1 in total

1.  The diagnostic value of CRP, IL-8, PCT, and sTREM-1 in the detection of bacterial infections in pediatric oncology patients with febrile neutropenia.

Authors:  Karin G E Miedema; Eveline S J M de Bont; Rob F M Oude Elferink; Michel J van Vliet; Claudi S M Oude Nijhuis; Willem A Kamps; Wim J E Tissing
Journal:  Support Care Cancer       Date:  2010-08-28       Impact factor: 3.603

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.